...Good morning, everybody. This is Paul Brennan, Managing Director of PolyNovo. With me today is Jan Gielen, our CFO; and David Williams, our Chairman. Apologies first up, for the delay this morning, a few technical issues on our end. The results are now launched with the ASX, both this presentation and other 4-A and the annual report, and I encourage you to download those and look at those. But we'll start this presentation, which is a summary. And then at the end, we'll take some Q&As. The format this morning is that I will show you through the highlights of the commercial activities and R&D, et cetera. And then we'll pass over to Jan for financial slides and then come back with FY '21 outlook and question and answers. Next slide, please. So if we look at the revenues for the year with NovoSorb BTM revenues have been up on FY '19 to be 104%, up year-on-year. This has been a very good result, particularly given the COVID situation globally; and our second half was actually stronger than...
